Ongoing review and analysis of the US and global solar panel market for both PV and thermal systems. Business development for launch of Tyll Solar product into selected target market segments to maximize penetration and ROI for prospective clients.

Work with Founder & CEO in two broad areas. The first, assessment of the viability of Australian technology R&D innovation and early development products to enter the US. If deemed viable, analysis, prospect client meetings and reports were prepared, mostly in healthcare and anti-counterfeit technology, The second involved the market research, development, presentation of a customer sales model in the pathology laboratory business to meet senior management strategic requirements.

Provide advice and documentation on solar energy market, particularly pertaining to size and growth of residential and commercial roof-top photovoltaic (PV) and solar Thermal (T) market segments. Research trends, government policies & incentives, competitors and forecast growth potential of hybrid PV-T technology in the US and other global market regions. Prepare business plans, presentations and Information Memorandum for investors.Incorporate the actual Tyll Solar hybrid PV-T prototype performance data and estimated production cost to assess market opportunity for US and global sales. regularly update competitor and market analysis to generate product attributes and benefits, as well as market penetration scenarios for discussion with strategic partners.

Responsible for pilots to establish licenses in US pathology market. Target market includes hospitals, commercial and specialized (esoteric) labs.The product, RippleDown, is new generation decision support software system with artificial intelligence has the ability to interface with existing systems and incrementally grow as required. New rules are added in a couple of minutes for any data requiring a decision, ie. new innovative diagnostic tests, changes in Medicare reimbursement, workflow, etc. Most importantly, this is all done in 'real time' by staff responsible for providing the service to customers, not IT staff with costly time consuming upgrades.Benefits include personalized interpretive comments on pathology reports for physicians, improved ordering, billing and reimbursement, increased autovalidation leading to better lab staff deployment compared to existing systems.

Lead the implementation of marketing and sales effectiveness programs in the Merck Asia Pacific region through training programs, feedback on business plans and procurement of more robust data, strategies and tactics to support business plans. Focused on Japan business transition from independent partially owned subsidiary to an integrated wholly owned and aligned Merck subsidiary in sales. Led regional development of a new business model which enabled a highly differentiated offering to customers. This model increased customer loyalty and enabled preferred provider status in chosen therapeutic markets with profitable increases in sales and market share.

Led the start-up and ongoing growth of the joint venture pharmaceutical company, AMRAD Pharmaceuticals, based in Melbourne, Australia for 12 years. Revenue reached over AUD 109 million and the company peaked as the seventh largest pharmaceutical company in Australia in retail sales, before being acquired by Merck, Sharp & Dohme, Australia in 2000. High profile corporate image together with strong product branding achieved to differentiate the company from competitors. Experience in the cardiovascular, gatrointestinal, central nervous system and oncology markets with ability to capture market share with smaller resources compared to larger competitors. Profit breakeven was passed in 18 months with a subsequent increase in annual profit every year thereafter.• Consolodated sales in 2000 were AUD 109 million with EBITA 10 million• LIPEX(simvastatin) achieved 40% share of simvastatin market with 25% of the resources• GRANOCYTE(lenograstim) achieved 40% share of GCSF market